Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.

Mini reviews in medicinal chemistry - 1 Jan 2023

Althaiban Abdullah, Thyagarajan Anita, Sahu Ravi Prakash

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is one of the highly aggressive malignancies and the leading cause of cancer-related deaths. Despite recent advancements, the overall therapeutic responses in PDAC patients remained relatively low or short-lived. While KRAS is the most frequently mutated proto-oncogene and represents a critical driver, it remains challenging to target all mutant variants. Thus, strategies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Line, Tumor
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 36573057
DOI: 10.2174/1389557523666221226095931

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.PMID 36573057Read ↗

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.Semantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.Semantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.Semantic proximity Read ↗

Challenges in Ras therapeutics in pancreatic cancer.Semantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.